The AIDD™ process both utilizes and builds our library at the same time. Instead of randomly generating a diverse compound library, Neurogen has chosen to bias or “enrich” its compound library in favor of selected families of compounds. Neurogen believes that to be successful in the drug discovery process, it is not the biggest or most diverse library that counts, but rather the richest and most intelligently designed.

AIDD builds and rationally enriches our compound library by relating functional molecules not just by their core structures, but also by their overall posture in chemical space; a process of identifying related groups of compounds that we call “Islands™”. Based on computer models of identified key characteristics, Neurogen uses high-speed synthesis combinatorial chemistry techniques to expand existing Islands and discover new ones. Newly synthesized compounds are tested against multiple targets via high throughput screening. The results of each cycle of synthesis, analysis and testing are exploited to refine AIDD models resulting in the design of better compounds and discovery of new Islands of high activity.

AIDD’s ability to design new compounds and to discover new Islands is accomplished not only by the testing of real compounds already in our enriched library, but by testing computer-designed molecules in a “virtual” library (numbering several hundred million virtual compounds that exists only as computer-based compound models) against computer-based target models. In this way, promising virtual compounds identified by virtual screening, can be actually synthesized, added to the real compound library, and tested against actual targets. The result is to both generate new Islands and refine the chemical leads previously identified until we discover compounds promising enough to move to the next phase of preclinical development.

We believe we possess one of the leading receptor biology teams in the world. We utilize this expertise in the design and construction of screening assays to capitalize on novel biological targets in our drug discovery efforts.

We focus on discovering novel drugs, designed to provide significant therapeutic advantages. We believe that our scientific expertise coupled with our AIDD system and our enriched library will allow us to continue to efficiently capitalize on highly validated targets where others have failed to discover successful drug candidates and to capitalize on the large number of targets that have resulted from the sequencing of the human genome

Accelerated Intelligent Drug Discovery system (AIDD) is an integrated system of hardware and software that allows Neurogen scientists to improve on the trial and error process traditionally associated with drug discovery and development.

This system incorporates automated robotics guided by state-of-the-art computerization, including neural network-based artificial intelligence, to design, model, synthesize and screen new chemical compounds.

Specifically, AIDD enables scientists to streamline and accelerate the drug discovery process through the effective and efficient iterative application of various phases of discovery.